Telomir Pharmaceuticals (NASDAQ: TELO) has announced new research findings from The Ohio State University College of Veterinary Medicine showing that its lead compound, Telomir-Zn, inhibited growth across human and canine osteosarcoma cell-line models at similar low drug concentrations. The study, led by Shay Bracha, DVM, MS, DACVIM (Oncology), evaluated Telomir-Zn in one human and two canine osteosarcoma models. These results support further translational investigation and a potential development pathway using naturally occurring canine osteosarcoma, which could accelerate progress toward human therapies.
The significance of this research lies in its cross-species applicability. Osteosarcoma is a devastating bone cancer that affects both humans and dogs, with limited treatment options and poor outcomes for advanced cases. By demonstrating that Telomir-Zn can inhibit growth in both human and canine cell lines at comparable low concentrations, the study suggests a conserved mechanism that could be targeted therapeutically. This opens the door to a translational approach where canine osteosarcoma, which occurs naturally in dogs at a higher rate, can serve as a model for human disease. Such an approach could expedite drug development by providing valuable efficacy and safety data before human trials.
Telomir is in discussions with The Ohio State University College of Veterinary Medicine and is assessing next steps for a potential in vivo efficacy study in canine osteosarcoma. If successful, this study could support both veterinary development and translational advancement toward human osteosarcoma. While the company's immediate focus remains its triple-negative breast cancer (TNBC) program, which is advancing toward site initiation and Phase 1/2 patient enrollment under an active FDA-cleared Investigational New Drug (IND) application, the osteosarcoma findings represent an important expansion of Telomir-Zn's potential. The TNBC program is currently the lead indication, but positive results in osteosarcoma could diversify the company's pipeline and open new markets.
Telomir Pharmaceuticals is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer. Telomir-Zn is designed to modulate intracellular metal homeostasis and epigenetic regulation. The compound has already received IND clearance from the U.S. Food and Drug Administration for a Phase 1/2 clinical trial in patients with advanced or metastatic TNBC. The new osteosarcoma data add to the growing body of evidence supporting Telomir-Zn's broad anticancer potential.
For investors, this announcement highlights Telomir's ability to generate data across multiple cancer types, potentially increasing the value of its pipeline. The osteosarcoma research, while early, could lead to a cost-effective development strategy leveraging veterinary trials. The company's focus on TNBC remains on track, with patient enrollment expected to begin. The latest news and updates relating to TELO are available in the company's newsroom at https://nnw.fm/TELO. To view the full press release, visit https://nnw.fm/laeGH. For more information about NetworkNewsWire, visit https://www.NetworkNewsWire.com.
